/
ATTO
$19.18+$1.12 (+6.20%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$16.15 – $22.79
46% from low
Exchange
NASDAQ
CS
Change$-5.18
Attovia Therapeutics, Inc. Common Stock
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
www.attovia.com- IPO / List date
- Aug 5, 2026
Held by traders on TradeandTell
No one on the platform currently holds ATTO.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ATTO as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2020-07-30 | 1-for-5.0270904666729reverse |
Recent trades on TradeandTell
No one on the platform has traded ATTO yet.
